scholarly journals Left Supraclavicular Lymphadenopathy as the Only Clinical Presentation of Prostate Cancer: A Case Report

2017 ◽  
Vol 17 (2) ◽  
pp. 41-44 ◽  
Author(s):  
Mohanad Abusultan ◽  
Pavel Hanzel ◽  
D. Durcansky ◽  
A. Hajtman
Keyword(s):  
Prostate Cancer ◽  
Lymph Nodes ◽  
Clinical Presentation ◽  
Cervical Lymphadenopathy ◽  
Cervical Lymph Node Metastasis ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Regional Lymph Nodes ◽  
Node Metastasis ◽  
Male Patients

AbstractProstate cancer usually metastasis to the regional lymph nodes and can rarely metastases to nonregional supradiaphragmatic lymph nodes. Cervical lymph node metastasis of prostate cancer is extremely rare. However, it should be considered in the differential diagnosis of cervical lymphadenopathy in male patients with adenocarcinoma of unknown primary site. In this report we present a rare case of metastatic prostate adenocarcinoma with left supraclavicular lymphadenopathy as the only clinical presentation with no other evidence of metastasis to the regional lymph nodes or bone metastasis.

scholarly journals Cervical lymphadenopathy as initial presentation of genito-urinary cancer

2019 ◽  
Vol 5 (6) ◽  
pp. 1739
Author(s):  
Sasanka K. Barua ◽  
Sarbartha K. Pratihar ◽  
Pranab K. Kaman ◽  
Atul Garg ◽  
Rajeev T. P. ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Head And Neck ◽  
Renal Cell ◽  
Cell Cancer ◽  
Cervical Lymphadenopathy ◽  
Papillary Renal Cell Carcinoma ◽  
Cervical Lymph Node Metastasis ◽  
Unknown Primary ◽  
Cervical Lymph Nodes ◽  
Primary Tumor Site

<p class="abstract">Head and neck cancers rank fifth amongst the most affected cancers in the world. Metastasis to cervical lymph nodes is primarily from sites in head and neck. About 1% of all malignant cervical adenopathies are encountered as metastasis from remote primary site. We present here our experience of four cases in last five years. Patients presented as cervical lymphadenopathy with unknown primary, which on evaluation was found to be of genitourinary source from different sites. It is a single centre retrospective study. We reviewed cancer registry. We found four cases of genitourinary cancer with cervical lymph node metastasis. Patients presented as cervical lymphadenopathy of unknown primary. Among those one papillary renal cell cancer with rhabdoid differentiation, one testicular cancer, two prostate cancer. One case was a 67 year male patient, who revealed papillary renal cell carcinoma with rhabdoid features. Another patient was a male of 31 years, who had left testicular mass with retroperitoneal and cervical lymphadenopathy. Two patients of 68 year and 74 year respectively had metastatic prostate cancer. All patients underwent proper treatment and regularly followed up. Although rare, malignant cervical lymphadenopathy may be the first clinical manifestation of metastasis from genitourinary tumors. Evaluation of genitourinary system must be included in the protocol for uncovering the primary tumor site in cases of isolated cervical adenopathy.</p><p class="abstract"> </p>

scholarly journals Mammary Analogue Secretory Carcinoma Presenting as a Cervical Lymph Node Metastasis of Unknown Primary Site: A Case Report

2017 ◽  
Vol 10 (1) ◽  
pp. 192-198 ◽  
Author(s):  
Kensuke Suzuki ◽  
Masao Yagi ◽  
Akira Kanda ◽  
Yoshiki Kobayashi ◽  
Masaya Konishi ◽  
...  
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cervical Lymph Node ◽  
Cervical Lymph Node Metastasis ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Node Metastasis ◽  
First Case

Background: Mammary analogue secretory carcinoma (MASC) is a pathological entity arising in the salivary glands first described by Skalova et al. [Am J Surg Pathol 2010;34: 599–608]. Here, we report the first case of MASC presenting as a cervical lymph node metastasis of unknown primary site together with a brief review of the literature. Case Report: We present a 74-year-old male with a painless lump in his left neck. Based on the fine-needle aspiration cytological findings, a possible malignant tumor was suspected. No evidence of a primary lesion was observed using imaging modalities including positron emission tomography/computed tomography. The patient underwent an ipsilateral modified radical neck dissection. Immunohistochemical staining showed that the neoplastic cells were positive for S100 protein and GATA3. A rearrangement of the ETV6 gene was noted during fluorescence in situ hybridization, and the final histopathological diagnosis was MASC. Conclusion: We encountered a MASC presenting as a cervical lymph node metastasis of unknown primary site. No adjuvant therapy was administered, and no local recurrence or metastatic disease has been detected during a follow-up period of 9 months. This is the first case report of MASC presenting as a cervical lymph node metastasis of unknown primary site and suggests the new properties of MASC.

scholarly journals Transitional cell carcinoma of urinary bladder with cervical lymph node metastasis: a case report and review of literature

2019 ◽  
Vol 6 (1) ◽  
pp. 194
Author(s):  
Ramya V. ◽  
Sahayaraj J.
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Urinary Bladder ◽  
Lymph Nodes ◽  
Cervical Lymph Node ◽  
Cervical Lymph Node Metastasis ◽  
Regional Lymph Nodes ◽  
Cervical Lymph Nodes ◽  
Node Metastasis

Bladder cancer usually spreads via the lymphatic and hematogenous routes, the common sites of metastases of urinary bladder cancers being the regional lymph nodes, liver, lung, bone, peritoneum, pleura, kidney, adrenal gland and intestines. Metastasis to non-regional lymph nodes especially cervical lymph nodes is extremely rare presentation. Metastasis to head and neck region is associated with poor prognosis and low survival rate. Here-in we report a case of cervical lymph node metastasis in patient with muscle invasive bladder cancer.

Cervical lymph node metastasis from an unknown primary site

Toukeibu Gan ◽  
2008 ◽  
Vol 34 (3) ◽  
pp. 459-463
Author(s):  
Hajime Ishinaga ◽  
Kazuya Otsu ◽  
Masayoshi Kobayashi ◽  
Atsushi Yuta ◽  
Kazuhiko Takeuchi
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cervical Lymph Node ◽  
Cervical Lymph Node Metastasis ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Node Metastasis

scholarly journals Extended-field intensity-modulated radiotherapy and dosage boost for lymph node metastasis are beneficial for the prognosis of FIGO IIICr and IVA cervical cancer patients with positive regional lymph nodes

2020 ◽  
Author(s):  
Yuhua Zhao ◽  
Gong Li ◽  
Lei Gao
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Intensity Modulated Radiotherapy ◽  
Figo Stage ◽  
Concurrent Chemotherapy ◽  
Regional Lymph Nodes ◽  
Free Survival ◽  
Node Metastasis ◽  
Extended Field

Abstract Background: This study aimed to evaluate the therapeutic efficacy of extended-field intensity-modulated radiotherapy (EF-IMRT) and dosage boost for positive lymph nodes, prognostic factors, treatment failure, and toxicity for Federation of Gynecology and Obstetrics (FIGO) stage IIICr and IVA cervical cancer patients with positive regional lymph nodes.Methods: We retrospectively evaluated 34 patients with stage IIICr and IVA who had received treatment in our institute between 2013 and 2016. Patients with stage IVA cervical cancer who had been enrolled in the analysis all had positive regional lymph nodes (pelvic or/and para-aortic). All 34 patients were treated with EF-IMRT and simultaneously integrated boost-IMRT (SIB-IMRT) for lymph node metastasis with concurrent chemotherapy and brachytherapy. Positive regional lymph nodes (short-axis diameter ≥5 mm in computed tomography [CT] or magnetic resonance imaging [MRI]) remaining after SIB-IMRT were then treated with sequential boost-IMRT (SeB-IMRT). The prognostic factors for overall survival (OS); disease-free survival (DFS); local control rate (LCR); regional control rate (RCR); distant metastasis-free survival (DMFS), including age, FIGO stage, pretreatment hemoglobin (HB) level, tumor size, para-aortic lymph node (PALN) metastasis, point A equivalent dose in 2-Gy fractions (EQD2 dose), concurrent chemotherapy, and adjuvant chemotherapy cycles, were analyzed.Results: Complete response (CR) was achieved in 31 (91.2%) patients with acceptable adverse effects. Notably, the three-year OS, DFS, LCR, RCR, DMFS for these patients were 73.5%, 70.6%, 88.1%, 87.9%, and 81.6%, respectively. In particular, the three-year OS, DFS, LCR, RCR, and DMFS of patients with positive PALNs was 41.7%, 33.3%, 65.6%, 72.2%, and 60.2%, respectively. The corresponding values in patients without positive PALNs were 90.9%, 90.9%, 100%, 95.5%, and 90.9%, respectively.Conclusions: Our study suggested that the EF-IMRT and nodal dosage boost decreased regional node failure and that patients with stage IIIC1r and IVA cervical cancer without PALN metastasis who received EF-IMRT and SIB-IMRT with or without SeB-IMRT had a significant survival advantage in terms of the DFS and OS.

scholarly journals Cervical Lymph Node Metastasis from an Unknown Primary Tumor

2003 ◽  
Vol 96 (4) ◽  
pp. 361-364
Author(s):  
Futoshi Watanabe ◽  
Etsuo Yamamoto ◽  
Yousaku Shiomi ◽  
Makito Tanabe ◽  
Keizo Fujiwara ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Primary Tumor ◽  
Cervical Lymph Node ◽  
Cervical Lymph Node Metastasis ◽  
Unknown Primary ◽  
Unknown Primary Tumor ◽  
Node Metastasis
Sign in / Sign up

Export Citation Format

Share Document